Skip to main content
OpenTrials
Completed

NCT Number: NCT04923516

Prevalence of Acute Hepatic Porphyria

To determine the proportion of patients suffering from acute hepatic porphyria (AHP) from different hospital departments and referred to an internist referent for a suggestive clinical picture with a first negative etiological assessment.

Completed

Looking for future studies?

Notify Me

Key information

About this study

In this context, this study aims to assess the prevalence of PHA in a population of patients with a suggestive clinical picture. A better knowledge of the pathology will make it possible to better guide patients and prevent them from diagnostic wandering fraught with physical and psychological consequences.

This is an observational, ambispective, transversal, multicenter study carried out in France. The goal is to recruit a cohort that will reflect current practice. 500 patients will be recruted.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Man or woman aged 18 to 60;
  • Presenting severe abdominal pain, afebrile and diffuse over several days, evolving for less than 5 years;
  • With at least one of the following symptoms:
  • Peripheral neurological symptoms: decreased driving force and pain in the limbs (roots of the thighs), etc. ;
  • Central neurological symptoms: psychiatric (depression, anxiety, insomnia), disturbances of consciousness, etc. ;
  • Autonomous neurological symptoms: tachycardia, nausea, vomiting, constipation, etc.
  • With a first negative etiological assessment requested by an emergency physician, gastroenterologist, gynecologist, neurologist, internist or another specialty, or with a diagnosis of acute hepatic porphyria less than 6 months;
  • Patient able to understand the information related to the study and having indicated his non-objection to the collection of data concerning him;

Exclusion criteria

  • Patient with a diagnosis of acute hepatic porphyria for more than 6 months;
  • Patient unfit to participate in the study, due to cognitive or linguistic difficulties;
  • Protected patient (under legal protection, or deprived of liberty by judicial or administrative decision).

Treatment and study plan

Dosage of Delta-aminolevulinic acid and Porphobilinogen

Other

Results of dosages of Delta-aminolevulinic acid and Porphobilinogen which are performed in accordance with the current practice will be recorded

Primary outcomes

  1. Binary criterion corresponding to the diagnosis of acute hepatic porphyria (acute hepatic porphyria + / acute hepatic porphyria -) via physiological parameter.

    Time frame: 1 day

    The diagnosis of acute hepatic porphyria is based on urine testing of the neurotoxic precursors of haem: Delta-aminolevulinic acid and Porphobilinogen. A patient will be considered to have acute hepatic porphyria (acute hepatic porphyria +) if:

    • Delta-aminolevulinic acid ≥ 3 µmol / mol Cr And or
    • Porphobilinogen ≥ 1 µmol / mol Cr Otherwise, the patient will be considered to be acute hepatic porphyria free (acute hepatic porphyria -).

Sponsors and collaborators

Lead sponsor

Association pour la Recherche en Medecine Interne

Network

Registry information

Official study title

Prevalence of Acute Hepatic Porphyria in Population With Suggestive Clinical Picture

Acronym: PHA

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Jun 11, 2021
Registry last updated
Jan 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.